A new kinetic method for the determination of serum adenosine deaminase (EC 3.5.4.4) is described, with adenosine as the substrate and nucleoside phosphorylase and xanthine oxidase as the reaction enzymes. lnosme is produced, which is converted to hypoxanthine. The hypoxanthine is oxidized to xanthine, which is further oxidized to uric acid. In these two reactions, blue 2,6-dichlorophenolindophenolis reduced to a colorless compound and the decrease in color is measured spectrophotometrically at 606 nm. The assay was automated by using a Cobas Mira analyzer. The automated assay had a CV of <7%, and the calibration curve was linear from 10 to 120 U/L The assay correlates well with an established method, based on detection of liberated NH3 with Berthelot's reaction. The reference interval (mean ± 2 SD) was 14-34 U/L (mean 24 U/L, n = 84). The enzymatic method described is easily automated and seems to be suitable for the routine determination of adenosine deaminase in serum.
The two methods generallyused rely on measuring the ammonia liberated from deamination by ADA. In the method of Giusti and Galanti (3) , ammonia is measured with Berthelot's reaction and is not easily automated; the method described by Ellis and Goldberg (9) measures the liberated ammonia enzymatically.
Both methods are subject to ammonia contamination. Optimization of the method. The reaction temperature was 37#{176}C. We examined the following buffers at various pH values: phosphate, Tris-HC1, and triethanolamine. The effects of variation in sample volumes, amount of secondary enzymes (NP; XOD) added, and concentration of DCII' were evaluated experimentally.
Automation.
After the optimized conditions were determined manually, the method was transferred to the Cobas Mira analyzer.
The automated version of the method was used in all studies done to evaluate the performance of the method.
Assay Validation

Accuracy.
Because no standard for ADA activity, under our conditions, was available, evaluation for accuracy was assessed by linearity studies and by comparison with an accepted alternative method (3).
Linearity.
We measured various dilutions of an ADA solution prepared from commercial ADA, and of serum samples containing high concentrations of ADA.
Precision. To assess within-run precision, we consecutively analyzed in a single run two control samples (freeze-dried pooled serum with and without added commercial ADA) with the proposed method. For betweenrun precision, we analyzed the same two controls singly in separate runs, each time with freshly prepared reagent.
Method comparison.
We compared the new method with the method described on the ADA activity). A lag phase of 120 s is usually observed. Figure 2 . 
For the
Assay Validation
Linearity. Figure 3 indicates linearity from -5 to -100 U/L. In additional studies, in which commercially prepared ADA was used, acceptable linearity was found up to values of at least 200 U/L (results not shown).
Precision. Data from the within-run and between-run determinations are reported in Table 1 .
Method comparison.
The data (83 patients and 10 control samples) obtained in the method comparison studiesare depictedin 
DiscussIon
In the studies undertaken to determine the stoichiom- Although the clinical value of serum ADA concentrations in patients is well documented (2-4), we are of the opinion that its potential usefulness
is not yet fully realized. One of the reasons for this might be technical difficulties in measuring S-ADA activity in the routine laboratory setting. The method we describe has overcome most of these difficulties, and we believe it may contribute to a more widespread use of S-ADA measurement in clinical diagnosis. The method is also suitable for the determination of ADA activity in other fluids such as effusions and cell extracts.
In conclusion, this new method proposed for measuring S-ADA has been found to have acceptable precision and reliabifity. It is easily automated and ideally suited for measuring S-ADA activity as a routine laboratory test.
